Quoin Pharmaceuticals Ltd. (QNRX) Paper Accepted; Phase 2/3 Interim Shows 66.7% Hit IGA Endpoint

Quoin Pharmaceuticals (QNRX) published a peer-reviewed paper on QRX003, showing a pediatric case improved from severe (IGA 4) to clear (IGA 0) in eight months. The patient maintained IGA 0 for 21 months with no adverse events. Phase 2/3 trial interim results showed 66.7% met the primary endpoint. Topline data is expected in Q2 2027.

Quoin Pharmaceuticals Ltd. (QNRX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy – Peer-Reviewed Paper Introducing QRX003 and Its Mechanism of Action in Netherton Syndrome Now Published – Case Report Details 21 Months of

Quoin Pharmaceuticals (QNRX) published a peer-reviewed paper on QRX003, showing a pediatric patient with Netherton Syndrome maintained clear skin and no itching for 21 months. The company is in late-stage trials for the rare dermatology treatment, with Phase 2/3 results expected in Q2 2027.

Canaccord Genuity initiated coverage on Quoin Pharmaceuticals (QNRX) with a buy rating and $18 price target, citing its lead drug QRX003 for Netherton syndrome. The stock is down 74% over a year. Phase 2/3 study met primary endpoint, with topline data expected in 2027. Canaccord projects 2028 launch and $300M peak sales. BTIG also initiated coverage with a buy rating and $14 target.

Quoin Pharmaceuticals (QNRX) received EMA Orphan Drug Designation for QRX003 to treat Peeling Skin Syndrome, a rare skin disorder. The designation offers development incentives and potential market exclusivity. QNRX plans to start clinical trials for PSS by year-end. QRX003 has also received U.S. and Japanese designations for rare diseases. QNRX stock closed at $4.15, down 4.82%.

Quoin Pharmaceuticals (QNRX) announced that the European Medicines Agency granted Orphan Drug Designation to its lead candidate QRX003 for Peeling Skin Syndrome. This status offers incentives and potential market exclusivity. The company is on track to launch a clinical study by year-end. Analysts have a $14.00 price target, but Spark's AI rates it Neutral due to financial performance and technicals.